1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy is a
1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. 1% of patients in each group experienced treatment-related mortality. Evidence Rating Level: 1 (Excellent) Study Rundown: Limited evidence exists on combined PD-1 and HER2 blockade with chemotherapy in HER2-positive gastro-esophageal cancer. This randomized controlled trial aimed to
Viktor Gruenwald, MD, PhD, discusses key results from a post hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma, highlighting the clinical implications of these results.
Jeffrey S. Weber, MD, PhD, highlighted key efficacy findings from the mRNA-4157-P201/KEYNOTE-942 trial, expanded on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma, and underscored the importance of continued research on mRNA vaccines paired with standard PD-1 therapy across cancer types.